Corcept Therapeutics Incorporated (CORT) Key Metrics
CORT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $11.91B
- Enterprise value
- $11.89B
- P/E (TTM)
- 244.8 10-yr median 26.9
- Forward P/E
- 19.3
- PEG ratio
- 0.81
- Price / sales
- 14.3 10-yr median 7.2
- Price / book
- 18.0 10-yr median 6.5
- EV / EBITDA
- — 10-yr median 23.5
- Dividend yield
- —
- Beta
- 0.40
CORT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCORT valuation Price multiples at each fiscal year-end price.
CORT returns How much profit the business earns on the capital it uses.
CORT per-share figures Results divided by the shares outstanding at year-end.
CORT financial health Debt, liquidity and how easily interest is covered.
CORT efficiency & capital use Working capital cycle and where the cash goes.
CORT valuation history
CORT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CORT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CORT cash returned to shareholders
CORT price vs earnings per share
CORT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $4.18B | $5.72B | $3.63B | $2.36B | $2.49B | $3.25B | $1.48B | $1.69B | $2.25B | $843.2M |
| Enterprise value | $3.81B | $5.34B | $3.26B | $1.92B | $2.27B | $2.77B | $1.21B | $1.49B | $2.14B | $806.3M |
| P/E ratio | 41.9 | 40.9 | 34.2 | 23.2 | 22.2 | 30.6 | 15.7 | 22.4 | 17.4 | 103.6 |
| Price / sales | 5.5 | 8.5 | 7.5 | 5.9 | 6.8 | 9.2 | 4.8 | 6.7 | 14.1 | 10.4 |
| Price / book | 6.4 | 8.4 | 7.2 | 4.7 | 6.6 | 6.2 | 4.0 | 6.1 | 11.8 | 20.4 |
| Price / free cash flow | 29.4 | 29.2 | 28.6 | 19.6 | 14.9 | 21.6 | 11.0 | 14.7 | 37.2 | 46.3 |
| Price / operating cash flow | 29.4 | 28.9 | 28.6 | 19.6 | 14.9 | 21.4 | 10.9 | 14.6 | 36.9 | 45.8 |
| EV / sales | 5.0 | 7.9 | 6.8 | 4.8 | 6.2 | 7.8 | 3.9 | 5.9 | 13.5 | 9.9 |
| EV / EBITDA | 55.7 | 32.8 | 25.7 | 16.6 | 17.8 | 21.3 | 10.6 | 16.6 | 40.5 | 78.5 |
| EV / free cash flow | 26.9 | 27.3 | 25.7 | 16.1 | 13.6 | 18.4 | 9.0 | 12.9 | 35.4 | 44.3 |
| Earnings yield | 2.4% | 2.4% | 2.9% | 4.3% | 4.5% | 3.3% | 6.4% | 4.5% | 5.7% | 1.0% |
| Free cash flow yield | 3.4% | 3.4% | 3.5% | 5.1% | 6.7% | 4.6% | 9.1% | 6.8% | 2.7% | 2.2% |
| Dividend yield | — | — | — | 1.0% | 0.6% | 0.7% | 0.5% | — | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 5.9% | 0.3% | 4.0% | 1.9% | 12.4% | 1.0% | 2.6% | 1.4% | 0.0% | 0.0% |
| Share price at fiscal year-end | $34.80 | $50.39 | $32.48 | $20.31 | $19.80 | $26.16 | $12.10 | $13.36 | $18.06 | $7.26 |
| Per share | ||||||||||
| Revenue per share | $6.35 | $5.95 | $4.32 | $3.47 | $2.91 | $2.85 | $2.50 | $1.98 | $1.28 | $0.70 |
| Earnings per share | $0.83 | $1.23 | $0.95 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 | $1.04 | $0.07 |
| Operating cash flow per share | $1.18 | $1.75 | $1.14 | $1.04 | $1.33 | $1.22 | $1.11 | $0.91 | $0.49 | $0.16 |
| Free cash flow per share | $1.18 | $1.73 | $1.14 | $1.03 | $1.33 | $1.21 | $1.10 | $0.91 | $0.49 | $0.16 |
| Cash per share | $3.10 | $3.38 | $3.30 | $3.72 | $1.77 | $3.84 | $2.25 | $1.63 | $0.84 | $0.44 |
| Book value per share | $5.40 | $5.99 | $4.53 | $4.33 | $2.98 | $4.21 | $3.03 | $2.18 | $1.53 | $0.36 |
| Tangible book value per share | $5.40 | $5.99 | $4.53 | $4.33 | $2.98 | $4.21 | $3.03 | $2.18 | $1.53 | $0.36 |
| Dividends per share | — | — | — | $0.21 | $0.11 | $0.17 | $0.06 | — | $0.00 | $0.00 |
| Capex per share | $0.00 | $0.02 | $0.00 | $0.00 | $0.00 | $0.01 | $0.01 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.05 | $0.06 | $0.00 | $0.01 | $0.00 | $0.02 | $0.03 | — | $0.00 | $0.13 |
| Shares outstanding | 120.0M | 113.5M | 111.7M | 116.0M | 126.0M | 124.2M | 122.6M | 126.7M | 124.5M | 116.1M |
| Change in shares outstanding | +5.7% | +1.6% | −3.6% | −7.9% | +1.4% | +1.3% | −3.3% | +1.7% | +7.2% | +8.7% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 15.0% | 23.6% | 21.0% | 23.1% | 25.0% | 23.7% | 29.1% | 32.3% | 111.1% | 27.2% |
| Return on invested capital (ROIC) | 15.3% | 54.2% | 87.1% | 87.7% | 111.0% | 139.9% | 107.4% | 93.9% | 115.6% | 201.6% |
| Return on assets (ROA) | 11.9% | 19.1% | 17.6% | 20.1% | 22.6% | 21.5% | 26.0% | 28.3% | 89.3% | 13.5% |
| Return on tangible assets | 11.9% | 16.6% | 17.1% | 17.4% | 26.6% | 18.5% | 22.8% | 24.2% | 58.5% | 11.8% |
| Free cash flow margin | 18.6% | 29.0% | 26.3% | 29.8% | 45.7% | 42.6% | 44.1% | 45.9% | 38.0% | 22.4% |
| Income quality (OCF / net income) | 1.42 | 1.42 | 1.20 | 1.19 | 1.49 | 1.43 | 1.45 | 1.53 | 0.47 | 2.26 |
| Financial health | ||||||||||
| Total debt | $6.1M | $6.9M | $151,000 | $1.1M | $526,000 | $2.6M | $3.5M | — | $0 | $14.7M |
| Cash & short-term investments | $372.2M | $383.3M | $368.2M | $431.7M | $223.5M | $476.9M | $276.0M | $206.8M | $104.0M | $51.5M |
| Net debt | −$366.0M | −$376.4M | −$368.1M | −$430.5M | −$223.0M | −$474.3M | −$272.5M | −$206.8M | −$104.0M | −$36.9M |
| Debt / equity | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — | 0.00 | 0.35 |
| Debt / assets | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | — | 0.00 | 0.21 |
| Net debt / EBITDA | −5.36 | −2.31 | −2.90 | −3.72 | −1.75 | −3.64 | −2.40 | −2.30 | −1.96 | −3.59 |
| Current ratio | 2.92 | 3.35 | 4.39 | 6.89 | 5.60 | 49.67 | 7.91 | 6.72 | 4.75 | 2.40 |
| Quick ratio | 2.85 | 3.26 | 4.31 | 6.80 | 5.50 | 47.67 | 7.77 | 6.26 | 4.47 | 2.31 |
| Interest coverage | — | — | — | 31.7 | 34.6 | 22.7 | 22.0 | 33.7 | — | 5.0 |
| Working capital | $319.4M | $330.8M | $354.1M | $426.8M | $218.9M | $513.7M | $268.5M | $204.8M | $111.0M | $38.3M |
| Invested capital | $281.8M | $303.2M | $138.6M | $71.3M | $152.8M | $49.0M | $98.7M | $69.1M | $86.9M | $4.5M |
| Tangible asset value | $647.8M | $679.6M | $506.7M | $501.8M | $375.8M | $523.3M | $371.2M | $275.9M | $191.0M | $41.4M |
| Net current asset value | $296.6M | $310.6M | $343.8M | $417.7M | $218.5M | $475.9M | $266.2M | $204.8M | $111.0M | $38.3M |
| Graham number | $10.04 | $12.88 | $9.84 | $9.23 | $7.74 | $9.00 | $7.24 | $5.40 | $5.98 | $0.75 |
| Graham net-net per share | $1.96 | $2.40 | $2.68 | $3.35 | $1.59 | $3.69 | $2.06 | $1.52 | $0.80 | $0.28 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | $23.9M | $14.2M | $21.5M | $7.0M | — | $0 | $0 |
| Share buybacks (net) | $245.9M | $15.7M | $145.4M | $21.7M | $296.0M | $9.9M | $31.0M | $23.7M | $0 | $0 |
| Dividend payout ratio | — | — | — | 23.5% | 12.6% | 20.3% | 7.4% | — | 0.0% | 0.0% |
| Dividends + buybacks / free cash flow | 173.4% | 8.0% | 114.6% | 38.0% | 185.3% | 20.9% | 28.1% | 20.5% | 0.0% | 0.0% |
| Capex / revenue | 0.0% | 0.3% | 0.0% | 0.1% | 0.1% | 0.3% | 0.4% | 0.1% | 0.3% | 0.2% |
| Capex / operating cash flow | 0.1% | 1.1% | 0.1% | 0.3% | 0.3% | 0.8% | 0.8% | 0.3% | 0.7% | 1.1% |
| Capex / depreciation | 0.11 | 1.63 | 0.06 | 0.12 | 0.15 | 0.55 | 0.50 | 1.26 | 3.95 | 2.23 |
| Stock-based compensation / revenue | 11.1% | 9.1% | 10.1% | 10.6% | 11.7% | 9.5% | 9.6% | 9.5% | 8.4% | 8.7% |
| R&D / revenue | 33.5% | 36.6% | 38.2% | 32.6% | 31.1% | 32.4% | 29.0% | 29.9% | 25.4% | 29.3% |
| SG&A / revenue | 58.9% | 41.5% | 38.2% | 38.0% | 33.4% | 29.8% | 32.7% | 32.4% | 39.2% | 55.6% |
| Efficiency | ||||||||||
| Days sales outstanding | 28.3 | 31.1 | 39.2 | 34.5 | 27.5 | 23.8 | 22.3 | 33.3 | 43.6 | 36.1 |
| Days of inventory on hand | 355.5 | 337.8 | 389.4 | 375.8 | 903.5 | 869.0 | 718.4 | 861.5 | 549.7 | 355.7 |
| Days payables outstanding | 785.0 | 549.6 | 827.1 | 640.0 | 603.4 | 591.5 | 524.0 | 589.5 | 558.1 | 320.6 |
| Cash conversion cycle (days) | -401.2 | -180.8 | -398.4 | -229.7 | 327.6 | 301.4 | 216.7 | 305.3 | 35.2 | 71.2 |
| Receivables turnover | 12.92 | 11.75 | 9.31 | 10.59 | 13.25 | 15.34 | 16.34 | 10.98 | 8.37 | 10.11 |
| Payables turnover | 0.46 | 0.66 | 0.44 | 0.57 | 0.60 | 0.62 | 0.70 | 0.62 | 0.65 | 1.14 |
| Inventory turnover | 1.03 | 1.08 | 0.94 | 0.97 | 0.40 | 0.42 | 0.51 | 0.42 | 0.66 | 1.03 |
| Asset turnover | 0.91 | 0.92 | 0.80 | 0.80 | 0.74 | 0.72 | 0.85 | 0.94 | 1.10 | 1.35 |
| Average receivables | $58.9M | $57.4M | $51.8M | $37.9M | $27.6M | $23.1M | $18.8M | $22.9M | $19.0M | $8.0M |
| Average payables | $27.9M | $16.4M | $14.7M | $9.4M | $8.7M | $9.0M | $7.9M | $8.4M | $5.4M | $1.8M |
| Average inventory | $12.6M | $10.1M | $6.9M | $5.5M | $13.1M | $13.3M | $10.8M | $12.3M | $5.4M | $2.0M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CORT's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CORT valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Corcept Therapeutics traded at 41.9 times earnings, against a 10-year median of 26.9. Based on the latest twelve months, the trailing P/E is 244.8 and the forward P/E is 19.3. Corcept Therapeutics earned a return on equity of 15.0% and a return on invested capital of 15.3% in fiscal 2025. It ended the year with $6.1 million of debt and $372.2 million in cash and short-term investments, a net cash position of $366.0 million. It returned $245.9 million to shareholders: $0 in dividends and $245.9 million in share buybacks, 173% of free cash flow. The share count rose 3.3% from 116.1M to 120.0M over 9 years.
See the CORT income statement, the CORT chart for price history, or the CORT stock overview for the latest quote and news.
CORT key metrics FAQ
What is Corcept Therapeutics's P/E ratio?
Corcept Therapeutics's trailing P/E ratio is 244.8 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 19.3. At the end of fiscal 2025 it was 41.9, compared with a 10-year median of 26.9.
What is Corcept Therapeutics's EV/EBITDA?
Corcept Therapeutics's enterprise value was 55.7 times EBITDA at the end of fiscal 2025 (enterprise value $3.8 billion, EBITDA $68.4 million).
What is Corcept Therapeutics's return on equity?
Corcept Therapeutics's return on equity (ROE) was 15.0% in fiscal 2025: net income of $99.7 million on average shareholders' equity of $663.7 million.
What is Corcept Therapeutics's ROIC?
Corcept Therapeutics's return on invested capital was 15.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Corcept Therapeutics have?
Corcept Therapeutics had total debt of $6.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
Does Corcept Therapeutics buy back its shares?
Yes. Corcept Therapeutics spent $245.9 million on net share repurchases in fiscal 2025 Shares outstanding changed +5.7% over the year, to 120.0M..
What is Corcept Therapeutics's free cash flow yield?
Corcept Therapeutics generated $141.8 million of free cash flow in fiscal 2025, a free cash flow yield of 3.4% on its market value at year-end ($4.2 billion).
What is Corcept Therapeutics's current ratio?
Corcept Therapeutics's current ratio was 2.92 at the end of fiscal 2025: current assets were 2.92 times current liabilities.